Technopath Clinical Diagnostics, Syosset, NY, has launched its Multichem ID-Covid-19 quality control solutions, offering laboratories third-party quality control products enabling an independent, totally unbiased assessment of a diagnostic device or method for covid-19 antibody testing.
“We are firmly resolute in supporting the global response to the covid-19 pandemic by manufacturing independent quality solutions helping diagnostic companies and laboratories get to optimal test performance as quickly as possible,” says Malcolm Bell, chief executive officer and founder of Technopath. “With some clinical labs processing up to 500,000 coronavirus antibody tests per month, the company is laser-focused on assuring the quality of patient testing, and we believe our third-party QC solutions will reduce potential errors, allowing laboratories to release patient results with confidence.”
“With antibody testing accelerating across nations, clinical laboratories should be demanding data on validation studies, sensitivity and specificity, and conducting those studies in their labs,” says James O. Westgard, PhD, longtime leader in clinical laboratory quality-control and founder of Westgard QC. “Quality control is one of the most critical aspects of laboratory testing, and laboratories need to be adding third-party controls to their methods as soon as possible.”
For more information, visit Technopath Clinical Diagnostics.
